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Tetanus is still a scourge among the under-privileged
populations of the world, and unfortunately remains
an important cause of death although a cheap, safe
and highly efficacious vaccine is available. The rarity of
the disease in some parts of the world results in newly
trained physicians being unable to make a clinical
diagnosis, and hampers the conduct of adequately
powered randomized controlled trials. Several new
and experimental pharmacological agents are being
used to control the spasms in tetanus, and to combat
the autonomic instability that occurs in the disease.
New evidence is emerging regarding the use of antibiotics
and intrathecal immunoglobulin in tetanus. It is imperative,
therefore, that all physicians working in critical care should
be aware of the current advances and evidence-based
guidelines for management of tetanus in order to achieve
the best outcomes, which Rodrigo and colleagues have
reviewed in a recent issue of Critical Care.port in patients with severe tetanus. This has, however,The past three decades have seen a marked reduction in
the global burden of tetanus, and following the cam-
paign directed at elimination of maternal and neonatal
tetanus, the World Health Organization estimates that
58,000 newborns died in 2010, a 93% reduction from the
situation in the late 1980s [1,2]. Several countries have
successful immunization programs in place, but tetanus
still continues to be an important, though hugely pre-
ventable, cause of mortality in several regions in the de-
veloping world [3,4]. Although tetanus toxoid was first
used extensively in the Second World War, the types of
wounds leading to tetanus have shown a recent trend to
be less severe and often trivial, possibly because more
serious wounds are generally given more expeditious
and thorough medical attention [4].* Correspondence: geetakkumar@gmail.com
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and impeccable management of tetanus cases, which is a
tough ask when physicians may not have experienced
cases during their period of training. The issue is com-
pounded by the fact that the diagnosis of tetanus is en-
tirely clinical, with hardly any role for investigative
modalities. Moreover, the management of tetanus is a
challenge even for most physicians experienced in the
care of such patients, and novices and old hands alike
should be supported by having access to current recom-
mendations and evidence-based therapeutic strategies.
The principles of management of tetanus include se-
dation and control of muscle spasms, neutralization of
tetanus toxin, prevention of production of tetanus toxin
by use of antibiotics to which Clostridium tetani is sus-
ceptible and by wound debridement, treatment of compli-
cations, including autonomic dysfunction, and supportive
care [5].
The improvement of facilities in ICUs has led to a shift
towards deep sedation, total paralysis and ventilator sup-
resulted in a paradoxical increase in ventilator- associ-
ated complications, and renewed interest in sedation
and control of muscle spasms by newer and often ex-
perimental pharmacological agents [6]. Moreover, faci-
lities for ventilator support are often limited in the very
same parts of the world where tetanus is still a bane to
contend with.
The narrative review of Rodrigo and colleagues [1]
takes a close look at the current evidence base for the
use of newer agents for control of muscle spasms, in-
cluding intravenous magnesium sulfate, intrathecal bac-
lofen, dantrolene and botulinum toxin. The main
stumbling blocks preventing widespread use of intra-
thecal baclofen were found to be the expensive intra-
thecal drug delivery system, the chance for infection and
the need for specialized care in an ICU, due to its pro-
pensity to cause cardiorespiratory instability [7].
Autonomic dysfunction is an important problem to be
tackled in patients with tetanus, since it may lead to a
fatal outcome if not addressed adequately. Rodrigo andCentral Ltd. The licensee has exclusive rights to distribute this article, in any
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drugs for this purpose, including intravenous morphine,
clonidine, labetalol and magnesium sulfate.
Several studies have looked into the route of adminis-
tration of tetanus immunoglobulin [8,9] and Rodrigo
and colleagues review the role of intrathecal immuno-
globulin in minute detail, and presents a bird’s eye view
of current thinking. The role of antibiotics is also fo-
cused on, and the advantages of using metronidazole
over crystalline penicillin are clearly spelt out.
The evidence-based review by Rodrigo and colleagues
was hampered by the varying scales used to classify the
severity of tetanus in different studies, and the lack of
firmly grounded evidence for use of time-tested thera-
peutic modalities, including benzodiazepines and anti-
biotics. The paucity of randomized controlled trials
due to the rarity of the illness and the ethical concerns
in withholding time-tested therapeutic modalities also
came into sharp focus. Since the focus is now on the
elimination of maternal and neonatal tetanus, the future
will see a shift toward tetanus due to non-obstetric
causes, including mass casualties. This includes iatro-
genic causes, including surgery under non-sterile condi-
tions, piercing of body parts, ritual scarification and
injections by drug abusers. The excessive use of muscle
relaxants by physicians not adequately adept in their use
is likely to result in an unfortunate increase in morbidity
and mortality as well.Conclusion
The most important factor that determines the outcome
in tetanus is undoubtedly the quality of supportive care
and the rapidity of initiation of treatment after a diagno-
sis has been made. Rodrigo and colleagues’ systematic
narrative review on the pharmacological management of
tetanus is a timely and exhaustive resource that will
benefit clinicians, researchers and students, and will go a
long way to ensuring that patients with tetanus get the
benefit of optimal management and, hence, the best
chance for intact survival.
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